Enzon Pharmaceuticals Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (31)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Enzon Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Enzon Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “4” cancer drugs in clinical pipeline. There are 2 cancer drugs by Enzon Pharmaceuticals which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Enzon Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Enzon Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Enzon Pharmaceuticals. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “4” cancer drugs in clinical pipeline. There are 2 cancer drugs by Enzon Pharmaceuticals which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Enzon Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Enzon Pharmaceuticals

  1.1 Business Overview

  1.2 Enzon Pharmaceuticals Pipeline Overview

 

2. Enzon Pharmaceuticals Cancer Drugs in Preclinical Phase

  2.1 Cancer Therapeutics - Molecular Templates

 

3. Enzon Pharmaceuticals Cancer Drugs in Phase-I

  3.1 MT 3724

 

4. Enzon Pharmaceuticals Cancer Drugs in Phase-II

  4.1 Firtecan Pegol

 

5. Enzon Pharmaceuticals Cancer Drugs in Phase-III

  5.1 Calaspargase Pegol

 

6. Marketed Cancer Drugs by Enzon Pharmaceuticals

  6.1 Pegaspargase

  6.2 Peginterferon Alfa-2b

 

7. No Development Reported in Cancer Drugs in Clinical Pipeline

  7.1 Anticancer Antibodies - Affitech AS

 

8. Discontinued in Cancer Drugs in Clinical Pipelin

  8.1 Cetermin

  8.2 Pegamotecan

  8.3 EZN 3042

  8.4 PEG Paclitaxel

  8.5 Leuprorelin Inhalation - Nektar Therapeutics

  8.6 Pegarginase - Enzon Pharmaceuticals


Figure 1-1: Enzon Pharmaceuticals Cancer Pipeline by Phase (%)

Figure 1-2: Enzon Pharmaceuticals Cancer Pipeline by Phase (Number)

Figure 1-3 Enzon Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Enzon Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)